Author(s): Chu LC, Eberhart CG, Grossman SA, Herman JG
Abstract Share this page
Abstract Epigenetic silencing of functionally important genes is important in the development of malignancies and is a source of potential markers for molecular detection. Primary central nervous system lymphoma (PCNSL) is an increasingly common tumor that has not been extensively examined for changes in promoter region methylation. We examined 14 tumor suppressor genes in 25 cases of PCNSL using methylation-specific PCR. Methylation was observed in DAPK (84\%), TSP1 (68\%), CRBP1 (67\%), p16(INK) (4a) (64\%), p14(ARF) (59\%), MGMT (52\%), RARbeta2 (50\%), TIMP3 (44\%), TIMP2 (42\%), p15(INK) (4b) (40\%), p73 (28\%), hMLH1 (12\%), RB1 (8\%) and GSTP1 (8\%). Promoter methylation of p14(ARF), p16(INK) (4a) and MGMT was correlated with loss of expression by immunohistochemical staining. The methylation of many of these genes in PCNSL is similar to that reported in other high-grade B-cell lymphomas. All 25 cases of PCNSL had methylation of at least 2 genes. Methylation of DAPK, p16(INK) (4a) or MGMT was found in 96\% of the tumors, suggesting simple marker strategies to detect circulating methylated DNA in serum that might facilitate early tumor detection. Our study provides insight into the epigenetic alterations in PCNSL and provides potential biomarkers of disease.
This article was published in Int J Cancer
and referenced in Journal of Blood Disorders & Transfusion